By Fineline Cube 
China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) announced strong growth in revenue and profit for the second quarter and first half of 2025. For the first half of 2025, the company’s revenue reached RMB 20.8 billion, marking a 20.6% year-on-year (YoY) increase. Q2 revenue alone stood at RMB 11.14 billion, up 24.9% YoY. Total profit amounted to RMB 9.907 billion, reflecting a substantial 96.2% YoY increase.
Revenue by Region
- U.S. Market: RMB 14.03 billion (69% of total), up 38.4% YoY.
- European Market: RMB 2.33 billion (11% of total), up 9.2% YoY.
- China Market: RMB 3.15 billion (15% of total), down 5.2% YoY.
- Japan, South Korea & Other Markets: RMB 0.9 billion (4% of total), up 7.6% YoY.
Revenue by Business Segment
- Chemistry Services: RMB 16.30 billion, +33.5% YoY.
- Biology Services: RMB 1.25 billion, +7.1% YoY.
- Testing Services: RMB 2.69 billion.
Outlook
Wuxi Apptec anticipates full-year 2025 revenue from continuing operations to achieve double-digit growth. The growth rate forecast has been revised upward from 10%-15% to 13%-17%. The company now expects overall full-year revenue to be in the range of RMB 42.5-43.5 billion, up from the previous estimate of RMB 41.5-43.0 billion. The company will continue to focus on its core CRDMO business and enhance operational efficiency.-Fineline Info & Tech